Company’s lead cancer technology is its Remote-Controlled Cancer Drug Delivery platform.
Click here for more information
SAN DIEGO–(BUSINESS WIRE)–Global Cancer Technology (“GCT”) announced today that it has launched an equity crowdfunding campaign under Regulation CF guidelines. Investing information is available by clicking here.
“A successful Reg CF fundraise will fast-forward our efforts to translate GCT’s innovative and patented technology and realize the potential to significantly improve anticancer treatment outcomes,” said John Clark, CEO.
GCT is developing its Remote-Controlled Drug Delivery platform technology, focused on delivering Scintillating NanoCrystals (SNCs): nanosized injectable particles linked to cancer drug molecules in order to transport to, and then selectively decimate, deep-seated tumors via extremely low-dose radiation remotely controlled outside the patient’s body. The SNC platform is exclusively licensed to the company from the University of California San Diego (UCSD). Inactive cancer drug molecules are attached to GCT’s nanosized scintillators made of nanocrystals that are activated at the tumor site by a very low dose of external radiation, designed to release the drug molecules’ full potency without harming surrounding tissue.
San Diego-based Global Cancer Technology is an emerging medical technology company with a robust pipeline focused on fighting cancer.
CAUTION: The company’s Scintillating NanoCrystals (SNCs) are not approved for human use at this time.